Literature DB >> 15879012

p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma.

Y S Guan1, Y Liu, X P Zhou, X Li, Q He, L Sun.   

Abstract

Transcatheter arterial chemoembolisation (TACE) has become the standard treatment for unresectable hepatocellular carcinoma (HCC). However, this method is often unsuccessful. The p53 gene, which is present as a mutant form in many human tumours, is known to have broad spectrum antitumour effects when expressed normally. In this study, we report a 23 year old patient with recurrent HCC who was treated with the p53 gene (Gendicine) combining TACE, which resulted in a good clinical prognosis.

Entities:  

Mesh：

Year:  2005        PMID： 15879012      PMCID： PMC1774668          DOI： 10.1136/gut.2005.069237

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  12 in total

1.  Multidetector CT in evaluating blood supply of hepatocellular carcinoma after transcatheter arterial chemoembolization.

Authors:  Yong-Song Guan; Xiao-Hua Zheng; Xiang-Ping Zhou; Juan Huang; Long Sun; Xian Chen; Xiao Li; Qing He
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

2.  Arterial chemoembolization for hepatocellular carcinoma.

Authors:  Jian Fan; Gao-Jing Ten; Shi-Cheng He; Jin-He Guo; Dong-Pei Yang; Guo-Ying Wang
Journal:  World J Gastroenterol       Date:  1998-02       Impact factor: 5.742

Review 3.  Non-surgical treatment of hepatocellular carcinoma.

Authors:  D Y Lin; S M Lin; Y F Liaw
Journal:  J Gastroenterol Hepatol       Date:  1997-10       Impact factor: 4.029

4.  Transcatheter arterial embolization for advanced hepatocellular carcinoma resulting in a curative resection: report of two cases.

Authors:  A Mizoe; J Yamaguchi; T Azuma; H Fujioka; J Furui; T Kanematsu
Journal:  Hepatogastroenterology       Date:  2000 Nov-Dec

5.  Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma.

Authors:  C C Hsia; Y Nakashima; S S Thorgeirsson; C C Harris; M Minemura; S Momosaki; N J Wang; E Tabor
Journal:  Oncol Rep       Date:  2000 Mar-Apr       Impact factor: 3.906

Review 6.  Progress in cancer gene therapy.

Authors:  G Kouraklis
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

7.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors:  Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

8.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

Review 9.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

10.  Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma.

Authors:  Jun Qian; Jochen Truebenbach; Florian Graepler; Philippe Pereira; Peter Huppert; Thomas Eul; Gundula Wiemann; Claus Claussen
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742
View more
  7 in total

1.  Targeting tumor suppressor networks for cancer therapeutics.

Authors:  Xuning Emily Guo; Bryan Ngo; Aram Sandaldjian Modrek; Wen-Hwa Lee
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

2.  Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition.

Authors:  Na Kong; Wei Tao; Xiang Ling; Junqing Wang; Yuling Xiao; Sanjun Shi; Xiaoyuan Ji; Aram Shajii; Silvia Tian Gan; Na Yoon Kim; Dan G Duda; Tian Xie; Omid C Farokhzad; Jinjun Shi
Journal:  Sci Transl Med       Date:  2019-12-18       Impact factor: 17.956

3.  p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: one-year follow-up.

Authors:  Yong-Song Guan; Yuan Liu; Qing He; Xiao Li; Lin Yang; Ying Hu; Zi La
Journal:  World J Gastroenterol       Date:  2011-04-28       Impact factor: 5.742

4.  Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up.

Authors:  Yong-song Guan; Yuan Liu; Qing Zou; Qing He; Zi La; Lin Yang; Ying Hu
Journal:  J Zhejiang Univ Sci B       Date:  2009-05       Impact factor: 3.066

Review 5.  Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

Authors:  Guang-Xia Chen; Shu Zhang; Xiao-Hua He; Shi-Yu Liu; Chao Ma; Xiao-Ping Zou
Journal:  Onco Targets Ther       Date:  2014-10-21       Impact factor: 4.147

6.  Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy.

Authors:  Yuling Xiao; Jiang Chen; Hui Zhou; Xiaodong Zeng; Zhiping Ruan; Zhangya Pu; Xingya Jiang; Aya Matsui; Lingling Zhu; Zohreh Amoozgar; Dean Shuailin Chen; Xiangfei Han; Dan G Duda; Jinjun Shi
Journal:  Nat Commun       Date:  2022-02-09       Impact factor: 14.919

7.  Efficacy of recombinant adenoviral human p53 gene in treatment of malignant pleural or peritoneal effusions.

Authors:  Xin Zhang; Yi Hu; Jinliang Wang; Sujie Zhang; Haitao Tao; Sun Jing; Baishou Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.